Sequent Medical, an Aliso Viejo, California-based neurovascular device company, has closed a $26.0m Series C venture capital financing.
The round was led by Delphi Ventures, with participation from existing investors Versant Ventures, US Venture Partners, and Domain Associates.
In conjunction with the funding, James Bochnowski of Delphi Ventures will join Sequent Medical’s Board of Directors.
Led by President and Chief Executive Officer Tom Wilder, Sequent Medical is dedicated to the development of innovative catheter-based technologies for neurovascular specialists and their patients. Based on its proprietary MicroBraid(TM) technology, the company has created the WEB Aneurysm Embolization System, an intrasaccular neurovascular embolization device that is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis. It has the CE Mark, and is available at select centers in Europe and other countries, but is not available for use in the United States.
Sequent Medical intends to use the capital to support its clinical, commercial, and technology development programs, including the WEB.
The company also has a European operation based in Bonn, Germany.